Molecular Partners share price logo

Molecular Partners

NASDAQ: MOLN

$4.35

as on

Molecular Partners Stock Performance

as on September 5, 2026 at 2:16 pm IST

  • $4.35
    $4.35
  • 52 Week's Low

    52 Week's High

    $3.53
    $5.36
    downward going graph

    18.85%

    Downside

    23.22%

    Upside

    downward going graph

Molecular Partners share price movements today

Previous Close
$4.35
Open
$4.35
Volume
1.8K
Market Cap
$155.9M
Day's Low - High
$4.35 - $4.35
52 Week Low - High
$3.53 - $5.36

Molecular Partners Historical Returns

1 Month Return
+ 4.57 %
3 Month Return
+ 10.69 %
1 Year Return
+ 22.02 %
3 Year Return
-27.5 %
5 Year Return
-78.67 %

Molecular Partners Stock Fundamentals & Key Indicators

Check Molecular Partners market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$155.9M

EPS (TTM)

-1.35

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.57

Industry PE ratio

-1.63

PEG Ratio

-0.09276255826402804

EBITDA

-55.4M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-67.67%

Molecular Partners Stock Valuation

Track how Molecular Partners P/E has moved over time to understand its valuation trends.

Molecular Partners in the last 5 years

  • Overview

  • Trends

Lowest (-8.50x)

December 31, 2021

Today (-2.10x)

December 31, 2025

Industry (-1.63x)

December 31, 2025

Highest (1.67x)

December 31, 2022

LowHigh

Today’s Price to Earnings Ratio: -2.10x

Molecular Partners vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Molecular Partners with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
SELL$155.9M-78.67%-2.570.00%NA
BUY$44.6B614.61%NA0.00%NA
BUY$141.1B181.73%32.2186.04%NA
BUY$60.2B-64.27%-18.66-12.57%NA
BUY$84.8B24.12%20.1484.86%0.44%

Stock Returns calculator for Molecular Partners Stock including INR - Dollar returns

The Molecular Partners stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Molecular Partners investment value today

Current value as on today

₹1,30,742

Returns

₹30,742

(+30.74%)

Returns from Molecular Partners Stock

₹22,020 (+22.02%)

Dollar Impact

₹8,722 (+8.72%)

Analyst Recommendation on Molecular Partners Stock

Based on 2 analysts

SELL

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'SELL' rating for Molecular Partners. Average target price of $10.68

Molecular Partners Share Price Target

Get share price movements and forecasts by analysts on Molecular Partners.

What analysts predicted

59.27%UPSIDE

Target Price

$10.68

Current Price

$4.35

Analyzed by

2 Analysts

Target

$10.68

Molecular Partners target price $10.68, a slight upside of 59.27% compared to current price of $4.35. According to 2 analysts rating.

Indian Investors' Interest in Molecular Partners Stock

Search interest for Molecular Partners Stock has increased by 1071% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:1071% versus previous 30 day period

Molecular Partners Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
2
1
0
-
-
-
-
-
-
-
Gross Profit
-11
-11
-10
-9
0
-
0
0
0
0
Operating Income
-15
-15
-14
-14
-17
-17
-14
-15
-13
-13
EBITDA
-10
-14
-15
-10
-17
-19
-14
-15
-12
-13
Interest Expense
0
0
0
0
0
0
-
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-11
-15
-16
-11
-18
-20
-14
-15
-13
-13
Income Tax Expense
-
-
-
0
-
-
-
-
-
-
Net Income
-11
-15
-16
-11
-18
-20
-14
-15
-13
-13
Net Profit Margin
-415.12%
-743.78%
-1495.30%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Molecular Partners Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
20
10
20
9
9
189
7
4
-
Gross Profit
2
-5
-23
-46
-46
138
-40
-42
-2
Operating Income
-25
-37
-36
-58
-63
116
-61
-61
-58
EBITDA
-24
-36
-33
-59
-60
119
-59
-51
-59
Interest Expense
0
0
0
0
0
0
0
0
0
Depreciation
1
0
2
2
2
2
2
2
2
Income Before Tax
-25
-37
-36
-62
-63
117
-61
-54
-61
Income Tax Expense
0
0
0
0
0
-
-
0
0
Net Income
-25
-37
-36
-62
-63
117
-61
-54
-61
Net Profit Margin
10.96%
-50.67%
-113.40%
-500.12%
-497.19%
73.23%
-579.80%
-855.81%
0.00%

Molecular Partners Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-11
-15
-16
-11
-16
-20
-14
-15
-13
-13
Operating Cash Flow
-17
-15
-13
-13
-17
-13
-12
-13
-14
-10
Investing Cash Flow
17
13
14
-4
34
14
14
14
-4
14
Financing Cash Flow
0
0
0
15
0
0
0
0
0
0
Change in Cash
1
-4
0
-1
17
0
-12
-13
-15
-11

Molecular Partners Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-25
-37
-36
-62
-63
117
-61
-54
-61
Operating Cash Flow
-40
-42
-1
-28
-90
118
-59
-59
-51
Investing Cash Flow
20
9
-19
-21
-22
-101
44
40
72
Financing Cash Flow
0
0
0
113
50
-1
-1
14
-1
Change in Cash
-18
-32
-23
58
-61
16
-20
-3
18

Mutual Funds that own Molecular Partners Stock

Check out the Mutual Funds with significant holdings in Molecular Partners.

Funds
Holdings
Shares Held
Fidelity Concord Street Trust
0.00265%
1070

Global Institutional Holdings in Molecular Partners

Funds
Holdings
Dimensional
0%

Molecular Partners News & Key Events

  • img

    Today's Timeline - 12 November

    Wed, 04:22 PM

    -

    Molecular Partners presents new data on MP0712, highlighting first human images and supporting mechanism of action for small cell lung cancer treatment.

Insights on Molecular Partners

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 479.0% return, outperforming this stock by 457.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 33.1% return, outperforming this stock by 61.2%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -13.14M → -13.78M (in $), with an average decrease of 4.9% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 2.73M → 681.0K (in $), with an average decrease of 49.7% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, MOLN stock has moved down by -3.3%

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
OrganisationMolecular Partners
HeadquartersWagistrasse 14, Schlieren, Switzerland, 8952
IndustryBiotechnology
CEODr. Patrick Amstutz Ph.D.
E-voting on sharesClick here to vote

Key Management of Molecular Partners

Name

Title

Dr. Michael Tobias Stumpp Ph.D.

Co-Founder, Executive VP of Projects & Member of Management Board

Mr. Alexander Zurcher

COO & Member of Management Board

Mr. Martin Steegmaier Ph.D.

Chief Scientific Officer & Member of the Management Board

Mr. Michael Pitzner

Executive VP of Partnering & General Counsel

Dr. Pamela A. Trail Ph.D.

Strategic Consultant

Mr. Daniel Steiner Ph.D.

Senior Vice President of Targeted Radio Therapeutics

Dr. Patrick Amstutz Ph.D.

Co-Founder, CEO, Member of Management Board & Director

Mr. Robert Hendriks

Senior VP of Finance & Member of Management Board

Ms. Renate Gloggner

Executive VP of People & Community and Member of Management Board

Dr. Philippe Legenne M.B.A., M.D.

Chief Medical Officer & Member of the Management Board

FAQs

What is Molecular Partners share price today?

Molecular Partners share price today is $4.35 as on at the close of the market. Molecular Partners share today touched a day high of $4.35 and a low of $4.35.

What is the 52 week high and 52 week low for Molecular Partners share?

Molecular Partners share touched a 52 week high of $5.36 on and a 52 week low of $3.53 on . Molecular Partners stock price today i.e. is closed at $4.35,which is 18.84% down from its 52 week high and 23.23% up from its 52 week low.

What is Molecular Partners's market capitalisation today?

Molecular Partners market capitalisation is $0.00T as on .

How to invest in Molecular Partners Stock (MOLN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Molecular Partners on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Molecular Partners Shares that will get you 0.3448 shares as per Molecular Partners share price of $4.35 per share as on September 5, 2026 at 8:46 am IST.

What is the minimum amount required to buy Molecular Partners Stock (MOLN) from India?

Indian investors can start investing in Molecular Partners (MOLN) shares with as little as ₹94.49 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.90 in Molecular Partners stock (as per the Rupee-Dollar exchange rate as on ). Based on Molecular Partners share’s latest price of $4.35 as on September 5, 2026 at 8:46 am IST, you will get 2.2989 shares of Molecular Partners. Learn more about fractional shares .

What are the returns that Molecular Partners has given to Indian investors in the last 5 years?

Molecular Partners stock has given -78.67% share price returns and 29.96% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?